---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-018242"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T21:57:50.215077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ardelyx sells up to $20M in tenapanor Japan royalties to HealthCare Royalty

## Summary
- Up to $20M total: $10M upfront, $5M on Japan regulatory approval for hyperphosphatemia, $5M if net sales exceed target by end of 2025.
- Royalties stem from Ardelyx's License Agreement with Kyowa Kirin for tenapanor in Japan.
- Agreement includes customary covenants restricting sale, lien, or forgiveness of the royalty stream.
- Events of default allow HealthCare Royalty to claim indemnification up to a liability cap.

## SEC filing metadata
- accession: 0001628280-22-018242
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828022018242/0001628280-22-018242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828022018242/ardx-20220629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-018242
- JSON: https://secwatch.observer/filing/0001628280-22-018242.json
- Plain text: https://secwatch.observer/filing/0001628280-22-018242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.